10.03.2010
- Facet Biotech has agreed to be acquired by Abbott Laboratories for $27 a share, topping a hostile offer of $17.50 a share made last year by Biogen Idec. Shares of Facet rose 67%...
22.01.2010
- Investors welcomed the announcement that Biogen Chief Executive James Mullen will be leaving the company, with some saying he had lost credibility as a leader. The move came less...
